Anti-CD138 [OC-46F2]
Catalogue Number: AB02724-23.0-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | Syndecan-1; SDC1; SYND1; SDC |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Rabbit |
| Clone: | OC-46F2 |
| Isotype: | IgG |
| Immunogen: | The original antibody was generated by selecting a human antibody phage display library from human melanoma cells and later on its by its expression in mammalian cells. |
| Application: | ELISA, FC, IF, WB, IHC, Blk |
Additional Text
Gene ID
6382
Gene Name
SDC1
Uniprot ID
P18827
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Application Notes
The original antibody inhibited vascular maturation and tumour growth in an experimental human melanoma model. The therapeutic efficacy of this antibody was also demonstrated in an experimental ovarian carcinoma model. OC-46F2 scFv version was used as a capture antibody in a solid phase sandwich ELISA (PMID: 26460958). The scFv version of this antibody was also used in the immunofluorescent and immunohistochemical analysis of melanoma tissues, human ovarian carcinomas, human normal ovary cells and SKMEL28 cells (PMID: 26460958, 26460958). Syndecan-1 expression on a panel of cell lines was analysed by flow cytometry using recombinant OC-46F2. The scFv antibody can also recognize purified human recombinant extracellular portion of syndecan-1 in a western blot assay. Mice treated with OC-46F2 scFv showed no co-distribution of syndecan-1 with vascular endothelial growth factor receptor 2 (VEGFR2), which is generally seen in intratumour melanoma microenvironment. (PMID: 23352437). Melanoma cells lose their ability to form tubule-like structures in vitro after blocking syndecan-1 using OC-46F2. In a human melanoma xenograft model the combined therapy using OC-46F2 and L19-IL2, an immunocytokine specific for the tumor angiogenic-associated B-fibronectin isoform(B-FN), led to a complete inhibition of tumor growth until day 90 from tumor implantation in 71% of treated mice (PMID: 26460958). The small immuno protein version of this antibody 46F2SIP was used in combination with L19-IL2 for combination therapy in a human ovarian carcinoma model (PMID: 31443604).
Short Description
This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques.
AB02724-23.0-BT Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations